IP Library Patent Application 17014324
Patent Application
App. No. 17/014,324

DRUG VEHICLE COMPOSITIONS AND METHODS OF USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/014,324
Abstract

The invention is directed to a topical lidocaine gel composition comprising lidocaine or a salt thereof, one or more nonionic surfactants, a polyethylene glycol, mannitol, magnesium chloride, sodium chloride and carboxymethyl cellulose. The invention is further directed to a method of inducing local anesthesia in an eye of a patient comprising topically applying compositions of the present invention to the eye of the patient.

Claims (40)

1 . A topical ophthalmological lidocaine gel composition comprising:

from about 3% to about 4% w/v lidocaine hydrochloride;

one or more nonionic surfactants having a total concentration from about 2% to about 6% w/v;

from about 0.25% to about 2.5% w/v of a polyethylene glycol having a molecular weight of from about 400 to about 20,000 Daltons;

from about 0.25% to about 1.5% w/v mannitol;

from about 0.05% to about 0.2% w/v magnesium chloride;

from about 0.1% to about 1.25% w/v sodium chloride; and

from about 0.1% to about 2% w/v of a cellulose derivative,

wherein w/v denotes weight by total volume of the composition.

2 . The composition of claim 1 , wherein the one or more surfactants are selected from the group consisting of polysorbates, poloxamers, polyoxyl castor oils and cyclodextrins.

3 . The composition of claim 2 , wherein the one or more surfactants are selected from the group consisting of polysorbate 80, poloxamer 407, poloxamer 188, polyoxyl 35 castor oil and hydroxypropyl-gamma-cyclodextrin.

4 . The composition of claim 3 , wherein polysorbate 80 is at a concentration from about 0.5% to about 2.0% w/v.

5 . The composition of claim 3 , wherein poloxamer 407 is at a concentration from about 0.5% to about 1.5% w/v.

6 . The composition of claim 3 , wherein poloxamer 188 is at a concentration from about 0.1% to about 0.5% w/v.

7 . The composition of claim 3 , wherein polyoxyl 35 castor oil is at a concentration from about 0.1% to about 0.5% w/v.

8 . The composition of claim 3 , wherein hydroxypropyl-gamma-cyclodextrin is at a concentration from about 0.5% to about 1.5% w/v.

9 . The composition of claim 1 , wherein the polyethylene glycol is from about 0.25% to about 0.75% w/v polyethylene glycol 400.

10 . The composition of claim 1 , wherein mannitol is at a concentration from about 0.5% to about 1% w/v.

11 . The composition of claim 1 , wherein magnesium chloride is at a concentration from about 0.05% to about 0.15% w/v.

12 . The composition of claim 1 , wherein sodium chloride is at a concentration from about 0.2% to about 0.6% w/v.

13 . The composition of claim 1 , wherein the one or more cellulose derivatives are selected from the group consisting of sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose.

14 . The composition of claim 13 , wherein the cellulose polymer is sodium carboxymethyl cellulose.

15 . The composition of claim 14 , wherein sodium carboxymethyl cellulose is at a concentration from about 0.5% to about 1.5% w/v.

16 . A method of inducing local anesthesia in an eye of a patient comprising topically applying the composition of claim 1 to the eye of the patient.

17 . A topical ophthalmological lidocaine gel composition comprising:

about 3.5% w/v lidocaine hydrochloride;

from about 0.5% to about 1.0% w/v polysorbate 80;

about 1.0% w/v poloxamer 407;

about 0.2% w/v poloxamer 188;

about 0.25% w/v polyoxyl 35 castor oil;

from about 0.5% to about 1.5% w/v hydroxypropyl-gamma-cyclodextrin;

about 0.5% w/v polyethylene glycol 400;

about 0.75% w/v mannitol;

about 0.1% w/v magnesium chloride;

about 0.4% w/v sodium chloride;

about 1.0% w/v sodium carboxymethyl cellulose; and

optionally, citrate buffer or phosphate buffer,

wherein w/v denotes weight by total volume of the composition.

18 . The composition of claim 17 , wherein the concentration of polysorbate 80 is about 1.0% w/v and the concentration of hydroxypropyl-gamma-cyclodextrin is about 1.5% w/v.

19 . A method of inducing local anesthesia in an eye of a patient comprising topically applying the composition of claim 18 to the eye of the patient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2022
From: PS THERAPY LTD.
To: PS THERAPY, INC.
Reel/Frame 060087/0448 →